Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options.

The rising prevalence of fungal infections, especially those caused by species, presents a major risk to global health. With approximately 1.5 million deaths annually, the urgency for effective treatment options has never been greater. spp. are the leading cause of invasive infections, significantly impacting immunocompromised patients and those in healthcare settings. , and the emerging species are categorized as highly dangerous species because of their pathogenic potential and increasing drug resistance. This review comparatively describes the formation of microbial biofilms of both bacterial and fungal origin, including major pathogens, thereby creating a novel focus. Biofilms can further complicate treatment, as these structures provide enhanced resistance to antifungal therapies. Traditional antifungal agents, including polyenes, azoles and echinocandins, have shown effectiveness, yet resistance development continues to rise, necessitating the exploration of novel therapeutic approaches. Antimicrobial peptides (AMPs) such as the anti-biofilm peptides Pom-1 and Cm-p5 originally isolated from snails represent promising candidates due to their unique mechanisms of action and neglectable cytotoxicity. This review article discusses the challenges posed by infections, the characteristics of important species, the role of biofilms in virulence and the potential of new therapeutic options like AMPs.